

9/1/2020

## Medicare Part D Formulary Change

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: **Effective 9/1/2020**

Drug	Reason	Cost sharing**	Restrictions***
TABRECTA 150 MG TABLET	New Drug	Tier 4	PA
TABRECTA 200 MG TABLET	New Drug	Tier 4	PA
TERIPARATIDE 20 MCG/DOSE (620 MCG/2.48 ML) SUBCUTANEOUS PEN INJECTOR	New Drug	Tier 5	PA QL

Future Removed Products: **Effective 9/1/2020**

Drug	Reason	Alternative*
didanosine 200 mg capsule, delayed release	Removed from Formulary	Please contact your doctor.
potassium chloride 40 meq/l in 5 % dextrose intravenous solution	Removed from Formulary	Please contact your doctor.
TROPHAMINE 6% INTRAVENOUS SOLUTION	Removed from Formulary	Please contact your doctor.

**Cost Sharing Tier Changes:** There were no cost sharing tier changes this month.

Mutual of Omaha Rx Value: 20193

\*Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

\*\*Please consult the plan benefit design for copay/coinsurance amounts

\*\*\*Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist [LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy